RxDoctor Payments DataLook up a doctor →

Mutahar Ahmed, MD

Urology · Maywood, NJNPI 1760451827

Payments from drug & device makers

$464,128in general payments, 2019–2025

Across 441 payments — averaging $1052.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$296K
  • Biotissue Holdings Inc.$70K
  • New Wave Endo-surgical Corp.$50K
  • Vascular Technology, Inc.$27K
  • Amniox Medical, Inc.$8K
  • Conmed Corporation$7K
  • plus $6K from 34 others

What the payments were for

  • Consulting fees$83,87020%
  • Speaking & faculty fees$49,05012%
  • Travel & lodging$38,0699%
  • Food & beverage$12,7173%
  • Education$230,40056%
  • Gifts$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$464,128 in reported general payments places this provider in the 95th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$556,765
Medicare patients
828
Services billed
6,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron49$48,858
GemtesaVibegron23$19,846
Solifenacin Succinate138$11,020
Tamsulosin Hcl588$10,568
AndrogelTestosterone13$9,163
Finasteride530$8,272
Silodosin33$3,363
Dutasteride51$2,916
Alfuzosin Hcl ErAlfuzosin Hcl75$2,239
Testosterone30$1,629
Tadalafil44$1,570
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst20$823
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip41$816
NitrofurantoinNitrofurantoin Macrocrystal19$647
Oxybutynin Chloride ErOxybutynin Chloride16$617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$141$48,85849 claims
Sumitomo Pharma America, Inc.Gemtesa$37$19,84623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 401 urology providers in New Jersey.

Other urology in Maywood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →